

# Contents

---

|          |   |           |
|----------|---|-----------|
| <b>1</b> | <b>History of James Parkinson and Kinnier Wilson</b>  | <b>1</b>  |
|          | <i>Kalyan B Bhattacharyya</i>   |           |
|          | • James Parkinson (1755–1824) 11  |           |
|          | • Samuel Alexander Kinnier Wilson (1878–1937) 15  |           |
| <b>2</b> | <b>Epidemiology of Parkinson’s Disease</b>  | <b>9</b>  |
|          | <i>Pragya Sinha, Ashok Kumar</i>  |           |
|          | • Descriptive Epidemiology 9  |           |
|          | • Analytical Epidemiology 14  |           |
| <b>3</b> | <b>Basal Ganglia Circuit Related to Movement Disorders</b>                                  | <b>24</b> |
|          | <i>Priya Jagota</i>   |           |
|          | • Basal Ganglia Structures 24   |           |
|          | • Basal Ganglia Circuit – the Motor Circuit 26  |           |
|          | • Diseases of the Basal Ganglia 27  |           |
| <b>4</b> | <b>Pathophysiological Neuronal Oscillations: Invasive Recordings from the Basal Ganglia</b> | <b>28</b> |
|          | <i>Arun Singh, Kai Bötzel</i>   |           |
|          | • Current Technologies for Invasive Recordings 28   |           |
|          | • Oscillations 28   |           |
|          | • Analysis 28   |           |
|          | • Aberrant LFP Oscillations Recorded from Basal Ganglia 29                                  |           |
|          | • Are there Medication / lesion / DBS effects? 30   |           |
|          | • Synchronized Neuronal Activity in other Movements Disorders 30                            |           |
|          | • Oscillations During Motor Tasks 30  |           |
|          | • Oscillations During Cognitive Functions 32  |           |
| <b>5</b> | <b>Animal Models of Parkinson’s Disease</b>   | <b>34</b> |
|          | <i>Juan Sebastian Yakisich</i>  |           |
|          | • Toxin Models 35   |           |
|          | • 6-OHDA 35   |           |
|          | • MPTP 35   |           |
|          | • Reserpine 36  |           |
|          | • Rotenone 36   |           |
|          | • Paraquat and Maneb 36   |           |
|          | • LPS 36  |           |
|          | • Methamphetamine 36  |           |

- Genetic Models 36
  - Ubiquitin C-terminal Hydrolase L1 (UCH-L1) 37
  - Combination models (Fusion Models) 38
- 6 Etiology and Pathogenesis of Parkinson's Disease 42**  
*Paul Birinder S*
- Genetic Factors 42
  - Environmental Factors 45
  - Pathogenesis of Parkinson Disease 46
- 7 New Insight into Parkinson's Disease Genetics 50**  
*Ciprian Popescu*
- 8 Nonmotor Symptoms of Parkinson's Disease 66**  
*Rizaldy Pinzon*
- 9 Cognitive Dysfunction in Parkinson's Disease 71**  
*Vitor Tumas*
- Neuropsychological Changes in Parkinson's Disease 72
  - Recommendations 74
- 10 Psychosis in Parkinson's Disease 76**  
*Ravi Yadav, Pramod Kumar Pal*
- Prevalence 77
  - Investigations 80
- 11 Impact of the Parkinson's Disease on the Heart 84**  
*Ivica Scuric, Franjo Baborski*
- Cardiac Denervation 84
  - Effect of the PD Therapy 85
- 12 The Application of Motor Imagery in Patients with Parkinson's Disease: A State of the Art 87**  
*Elke Heremans, Peter Feys, Alice Nieuwboer, Werner F Helsen*
- Cardiac Denervation 84
  - Motor Imagery: A new Technique within Neurological Rehabilitation 87
  - Evaluation of Motor Imagery Ability 88
  - Facilitation of Motor Imagery Quality 89
- 13 The Role of Tremor Analysis in Parkinson's Disease 92**  
*Norbert Kovacs, Jozsef Janszky, Ferenc Nagy*
- Introduction and aims 92
  - Physiological and Pathological Tremors 92
  - Tremor Analysis 93
  - Quantification of Tremor Characteristics 98
  - Tremor Analysis for Differential Diagnosis 102
  - Tremor Analysis for Measuring Efficacy of Pharmacological and Surgical therapies 106
  - Tremor Analysis in Clinical Research 106

|           |   |            |
|-----------|---|------------|
| <b>14</b> | <b>Young Onset Parkinson's Disease</b>  | <b>112</b> |
|           | <i>Vinay Goyal, Bhavna Kaul</i>   |            |
| <b>15</b> | <b>Management of Early Parkinson's Disease</b>  | <b>115</b> |
|           | <i>Pratap Sanchetee</i>   |            |
|           | • Diagnosis 115   |            |
|           | • Drugs 116   |            |
|           | • Selection of Drug 118   |            |
|           | • Timing of Treatment 119   |            |
|           | • Non Motor Symptoms 119  |            |
|           | • Complementary and Supportive Therapies 120  |            |
| <b>16</b> | <b>Levodopa in Movement Disorders</b>   | <b>122</b> |
|           | <i>Sandeep Kaushal, Kanchan Gupta</i>   |            |
|           | • History of Levodopa (L-dopa) 122  |            |
|           | • Pharmacological Effects 123   |            |
|           | • Pharmacokinetics 123  |            |
|           | • Therapeutic uses of L-dopa 124  |            |
|           | • Important Issues with the Use of L-dopa (Table 16.2) 126                                      |            |
|           | • Important Drug Interactions <sup>2</sup> (Table 16.5) 128                                     |            |
|           | • Contraindications <sup>4</sup> (Table 16.6) 129   |            |
| <b>17</b> | <b>Apomorphine, Duodopa or DBS—Last Line Treatment Options for Advanced Parkinson's Disease</b> | <b>131</b> |
|           | <i>Dušan Flisar, Andreja Avberšek</i>   |            |
|           | • Duodenal levodopa Infusion 131  |            |
|           | • Continuous Subcutaneous Apomorphine Infusion 132  |            |
|           | • Deep Brain Stimulation 133  |            |
| <b>18</b> | <b>Vascular Parkinsonism</b>  | <b>137</b> |
|           | <i>Deepak Gupta, Abraham Kuruvilla</i>  |            |
|           | • Historical Aspects 137  |            |
|           | • Epidemiology 137  |            |
|           | • Pathophysiology 137   |            |
|           | • Pathology 139   |            |
|           | • Clinical Features 139   |            |
|           | • Imaging 142   |            |
|           | • Diagnostic Criteria 142   |            |
|           | • Differential Diagnosis 142  |            |
|           | • Treatment 144   |            |
|           | • Case Vignette 144   |            |
| <b>19</b> | <b>Progressive Supranuclear Palsy (PSP)</b>   | <b>147</b> |
|           | <i>Venkatesh Krishnamurthy</i>  |            |
|           | • Historical perspective 147  |            |
|           | • Genetics 147  |            |
|           | • Epidemiology 148  |            |
|           | • Clinical features 148   |            |

- PSP—Clinical Subtypes 150
  - Diagnostic Criteria 150
  - Pathology 150
  - Neuroimaging 151
  - Diagnostic Workup 152
  - Prognosis and Complications 152
  - Treatment 153
- 20 Multiple System Atrophy 158**
- Han-Joon Kim*
- History 158
  - Epidemiology 158
  - Clinical Features 158
  - Diagnostic Criteria 159
  - Differential Diagnosis 160
  - Pathology 160
  - Investigations 161
  - Pathogenesis 162
  - Treatment 162
  - Clinical Course and Prognosis 163
- 21 Corticobasal Degeneration 164**
- Anhar Hassan*
- Neuropathology 164
  - Clinical Features 164
  - Neuropsychology 166
  - Neuroimaging 166
  - Pathogenesis 167
  - Biomarkers 167
  - Treatment 167
  - Future Approaches 168
- 22 Neuropsychology of Parkinson-Plus Syndromes 172**
- Elena Baratelli, Cecilia Rassiga, Chiara Emilia Rosci*
- Part One 172
  - Part Two 179
- 23 Autonomic Functions in Parkinson's Disease and Other Movement Disorders 193**
- TN Sathyaprabha, Kaviraja Udupa, Raju TR*
- Pathophysiological Involvement of Autonomic Centers in PD 193
  - Autonomic Symptoms in PD 194
  - Gastrointestinal Symptoms 194
  - Cardiovascular Symptoms 194
  - Urogenital Symptoms 195
  - Thermoregulatory Symptoms 195
  - Studies Investigating Autonomic Involvement in PD 199
  - Cardiac Autonomic Involvement as a Marker of pre-PD 199
  - Autonomic Functions in other Movement Disorders 199
  - Future Directions 200

|  |            |
|--|------------|
| <b>24 Tremors: Clinical Diagnosis and Treatment</b>                    | <b>203</b> |
| <i>Prashanth LK, R Shiva Kumar, S Raghavendra, Abraham Kuruvilla</i>   |            |
| • Historical Aspects   | 203        |
| • Clinical Definition  | 203        |
| • Classification of Tremor   | 203        |
| • Etiology of Tremors  | 204        |
| • Tremor Assessment Scales   | 205        |
| • Clinical Characteristics and Management of Various types of Tremors  | 205        |
| <b>25 Essential Tremor</b>   | <b>212</b> |
| <i>Krishe Menezes, Selena C Nicholas Bublick, Lawrence W Elmer</i>     |            |
| • Definition of a Tremor   | 212        |
| • Pathophysiology  | 212        |
| <b>26 MR Imaging in Essential Tremor</b>                               | <b>217</b> |
| <i>Achyuta Nand Jha, Chandrajit Prasad, Santosh Kumar, Ashok Kumar</i> |            |
| <b>27 Wilson's Disease</b>   | <b>222</b> |
| <i>VM Dayal, Ashok Kumar</i>   |            |
| • Copper Metabolism  | 222        |
| • Molecular Biology  | 222        |
| • Clinical Features  | 223        |
| • Pathologic Features  | 224        |
| • Staging  | 224        |
| <b>28 Dystonia</b>   | <b>230</b> |
| <i>Tushar Gosavi, Kumar M Prakash</i>                                  |            |
| • Clinical Features of Dystonia in General                             | 230        |
| • Classification of Dystonia   | 230        |
| • Etiology/Causes of Dystonia  | 232        |
| • I. Primary Torsion Dystonia (PTD)                                    | 232        |
| • II. Dsytonia Plus Syndromes  | 233        |
| • III. Heredodegenerative Dystonias                                    | 234        |
| • Clinical Features of Specific Dysto-nias                             | 234        |
| • Diagnostic Approach to Dystonia                                      | 236        |
| <b>29 Dopa Responsive Dystonia</b>                                     | <b>242</b> |
| <i>Nirendra K Rai, Ashok Kumar</i>                                     |            |
| • Introduction and Brief History                                       | 242        |
| • Clinical Features  | 242        |
| <b>30 Writer's Cramp</b>   | <b>250</b> |
| <i>Brian D Berman</i>  |            |
| • Clinical Manifestations  | 250        |
| <b>31 Meige's Syndrome</b>   | <b>257</b> |
| <i>Prashanth LK, R Shiva Kumar, S Raghavendra, Abraham Kuruvilla</i>   |            |
| • Historical Aspects   | 257        |

- Epidemiology and Risk Factors 257
- Classification 257
- Pathophysiology 258
- Clinical Features 258
- Clinical Course 259
- Management 259

|           |   |            |
|-----------|---|------------|
| <b>32</b> | <b>Catatonia</b>  | <b>262</b> |
|           | <i>Balram Pandit, AS Srivastava</i>   |            |
|           | <ul style="list-style-type: none"> <li>• Historical Background 262</li> <li>• Nosology 263</li> <li>• Epidemiology 263</li> <li>• Etiology 263</li> <li>• Genetic Factors 263</li> <li>• Biochemical Factors 263</li> <li>• Psychosocial and Psychoanalytical Theories 265</li> <li>• Modern Theorists 266</li> <li>• Clinical Features 266</li> <li>• Forms of Catatonia 267</li> <li>• Course and Prognosis 271</li> <li>• Prevention 272</li> </ul>                      |            |
| <b>33</b> | <b>Hemifacial Spasm: Clinical Features and Management</b>   | <b>277</b> |
|           | <i>Pavesi Giacomo, Costella Giovanni Battista, Zara Gabriella</i>   |            |
|           | <ul style="list-style-type: none"> <li>• Functional Anatomy of the Facial Nerve 277</li> <li>• Clinical and Epidemiological Features of Hemifacial Spasm (HFS) 278</li> <li>• Differential Diagnosis 279</li> <li>• Etiology of HFS 279</li> <li>• Pathophysiology of HFS 280</li> <li>• Quality of Life (QoL) Measures in HFS 280</li> <li>• Diagnosis of HFS 280</li> <li>• Pharmacological Treatment of HFS 281</li> <li>• Neurosurgical Treatment of HFS 282</li> </ul> |            |
| <b>34</b> | <b>Chorea: An Update</b>  | <b>287</b> |
|           | <i>Fernando Vazquez-Sanchez, Adrian Ares-Luque</i>  |            |
|           | <ul style="list-style-type: none"> <li>• Clinical Features 287</li> <li>• Pathophysiology 287</li> <li>• Treatment 293</li> </ul>   |            |
| <b>35</b> | <b>Huntington's Disease</b>   | <b>295</b> |
|           | <i>Rohit Bhatia, Bhavna Kaul, Surekha Dabla</i>   |            |
|           | <ul style="list-style-type: none"> <li>• Clinical Features 295</li> <li>• Epidemiology 296</li> <li>• Differential Diagnosis 296</li> <li>• Treatment 297</li> </ul>  |            |
| <b>36</b> | <b>Rheumatic Chorea</b>   | <b>301</b> |
|           | <i>Bhaskar Ghosh, Shyamal Kumar Das</i>   |            |
|           | <ul style="list-style-type: none"> <li>• Epidemiology 301</li> </ul>  |            |

|           |  |            |
|-----------|--|------------|
|           | <ul style="list-style-type: none"><li>• Pathogenesis 301</li><li>• Clinical Features 301</li><li>• Diagnosis 302</li><li>• Prognosis 302</li><li>• Treatment 303</li></ul>   |            |
| <b>37</b> | <b>Athetosis</b>   | <b>305</b> |
|           | <i>Sangeeta Chaal</i>  |            |
|           | <ul style="list-style-type: none"><li>• Introduction/definition 305</li><li>• Clinical Features 305</li><li>• Drugs 307</li><li>• Management 309</li></ul>   |            |
| <b>38</b> | <b>Hemiballismus</b>   | <b>310</b> |
|           | <i>Lakshmi Narasimhan R, Kannan V, Venkatesh Perumalsamy, Jeyaraman R</i>  |            |
|           | <ul style="list-style-type: none"><li>• Definition 310</li><li>• Clinical Description 310</li><li>• Anatomical Localization 310</li></ul>  |            |
| <b>39</b> | <b>PANDAS</b>  | <b>316</b> |
|           | <i>Ashok Kumar</i>   |            |
|           | <ul style="list-style-type: none"><li>• Immune System and Psychiatric Dis-orders 316</li></ul>   |            |
| <b>40</b> | <b>Tics</b>  | <b>321</b> |
|           | <i>Tamar Ediberidze, Ashok Kumar</i>   |            |
| <b>41</b> | <b>Myoclonus</b>   | <b>325</b> |
|           | <i>Anup Bhattacharya</i>   |            |
| <b>42</b> | <b>Startle Syndrome</b>  | <b>332</b> |
|           | <i>Anita Arsovska, Zoran Arsovski, Ante Popovski</i>   |            |
| <b>43</b> | <b>Stereotypies</b>  | <b>344</b> |
|           | <i>Kuljeet Singh Anand, Mina Chandra</i>   |            |
|           | <ul style="list-style-type: none"><li>• Historical Aspects 344</li><li>• Definition 344</li><li>• Differential Diagnosis 344</li><li>• Classification 345</li><li>• Primary Stereotypies 346</li><li>• Secondary Stereotypies 346</li><li>• Etiopathology 347</li><li>• Complications 348</li><li>• Investigations 348</li><li>• Treatment 348</li></ul> |            |
| <b>44</b> | <b>Gait Disorders</b>  | <b>351</b> |
|           | <i>Amit Batla</i>  |            |
|           | <ul style="list-style-type: none"><li>• The gait cycle, Physiology and Examination for clues to Diagnosis of Gait Disorder 351</li><li>• Gait Disorders 353</li><li>• Pathophysiology of Gait Disorders 353</li></ul>  |            |

- Classification of Gait Disorders 353
  - Causes of Gait Disorders 353
  - Specific Gait Disorders 353
  - Dyskinetic Gait 354
  - Assessment and Scoring of Gait 354
  - Treatment of Gait Disorders 355
- 45 Hereditary Ataxias: An Overview and Indian Perspectives 362**  
*Achal Kumar Srivastava, Mohammed Faruq*
- Classification of Hereditary Ataxias 362
  - Spinocerebellar Ataxia: Overview 363
- 46 Paroxysmal Dyskinesias 394**  
*Tânia Lampreia, José Vale*
- Historical Aspects 394
- 47 Psychogenic Movement Disorders 406**  
*Sanjay Pandey*
- 48 Movement Disorders and Epilepsy 410**  
*Manjari Tripathi, Deepti Vibha*
- Clinical Imitators 410
- 49 Structural MR Imaging in Movement Disorders 416**  
*Robert Semnic, Aleksandar Jesic, Dusko Kozic, Marija Semnic*
- Parkinsonism 416
- 50 Emergencies in Movement Disorders 426**  
*Bindu Menon*
- Disorders of Spinal Rigidity in Man 428
  - Serotonin Syndrome 429
- 51 Movement Disorders in Children 431**  
*R Shiva Kumar, Prashanth LK, S Raghavendra, Abraham Kuruvilla*
- Description of Movement Disorders 432
  - Clinical Approach to a child with Abnormal Movements 432
- 52 Idiopathic Normal Pressure Hydrocephalus 447**  
*Teruo Kimura, Masatsune Ishikawa, Nobumasa Kuwana*
- Background 447
  - Hypothesis 447
  - Epidemiology –incidence Rate 448
  - Clinical Symptoms 448
  - Prognosis and Outcome 464
- 53 Botulinum Toxin in Movement Disorder 469**  
*Vinay Goyal, Ajanta Keshavraj, Chanchal Goyal*
- Hemifacial Spasm 469
  - Blepharospasm 470
  - Oromandibular Dystonia 470
  - Writer's Cramp 470

|  |     |            |
|--|-----|------------|
| • Spasmodic Dystonia                                   | 470 |            |
| • Adductor Laryngeal Breathing Dysphonia               | 470 |            |
| • Cervical Dystonia (CD)                               | 471 |            |
| • Spasticity   | 471 |            |
| • Sialorrhea   | 471 |            |
| • Acknowledgement and Declaration                      | 471 |            |
| <b>54 Deep Brain Stimulation in Movement Disorders</b> |     | <b>473</b> |
| <i>Pettarusp M Wadia</i>                               |     |            |
| • Deep Brain Surgery for Parkinson's Disease           | 473 |            |
| • Deep Brain Surgery for Dystonia                      | 474 |            |
| • Deep Brain Surgery for Tremors                       | 476 |            |
| • DBS in other Movement Disorders                      | 476 |            |
| <b>55 Role of Physiotherapy in Parkinson's Disease</b> |     | <b>479</b> |
| <i>Josni Khah, Binay Pandey, Ashok Kumar</i>           |     |            |
| • Symptoms   | 479 |            |
| • Examination  | 480 |            |
| • Treatment Goals                                      | 480 |            |
| • Therapeutic Interventions                            | 480 |            |
| <i>Index</i>   |     | <b>483</b> |